| Nivolumab in previously untreated melanoma without BRAF mutation C Robert, GV Long, B Brady, C Dutriaux, M Maio, L Mortier, JC Hassel, ... New England journal of medicine 372 (4), 320-330, 2015 | 6004 | 2015 |
| First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer BJ Solomon, T Mok, DW Kim, YL Wu, K Nakagawa, T Mekhail, E Felip, ... New England Journal of Medicine 371 (23), 2167-2177, 2014 | 3561 | 2014 |
| Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer J Bernier, C Domenge, M Ozsahin, K Matuszewska, JL Lefèbvre, ... New England Journal of Medicine 350 (19), 1945-1952, 2004 | 3356 | 2004 |
| Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2–positive metastatic breast … M Marty, F Cognetti, D Maraninchi, R Snyder, L Mauriac, M Tubiana-Hulin, ... Journal of clinical oncology 23 (19), 4265-4274, 2005 | 2013 | 2005 |
| Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised … E Pujade-Lauraine, JA Ledermann, F Selle, V Gebski, RT Penson, ... The lancet oncology 18 (9), 1274-1284, 2017 | 1649 | 2017 |
| Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non–small-cell lung cancer GV Scagliotti, R Fossati, V Torri, L Crino, G Giaccone, G Silvano, ... Journal of the National Cancer Institute 95 (19), 1453-1461, 2003 | 815 | 2003 |
| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ... The lancet oncology 18 (12), 1688-1700, 2017 | 640 | 2017 |
| Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. L Serrone, M Zeuli, FM Sega, F Cognetti Journal of experimental & clinical cancer research: CR 19 (1), 21-34, 2000 | 521 | 2000 |
| PTEN: multiple functions in human malignant tumors M Milella, I Falcone, F Conciatori, U Cesta Incani, A Del Curatolo, ... Frontiers in oncology 5, 24, 2015 | 505 | 2015 |
| Cancer in the elderly: why so badly treated? IS Fentiman, U Tirelli, S Monfardini, M Schneider, J Festen, F Cognetti, ... The Lancet 335 (8696), 1020-1022, 1990 | 445 | 1990 |
| Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy A Pace, A Savarese, M Picardo, V Maresca, U Pacetti, G Del Monte, ... Journal of Clinical Oncology 21 (5), 927-931, 2003 | 415 | 2003 |
| A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis A Alimonti, C Nardella, Z Chen, JG Clohessy, A Carracedo, LC Trotman, ... The Journal of clinical investigation 120 (3), 681-693, 2010 | 414 | 2010 |
| Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus D Del Bufalo, L Ciuffreda, D Trisciuoglio, M Desideri, F Cognetti, G Zupi, ... Cancer research 66 (11), 5549-5554, 2006 | 403 | 2006 |
| Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. F Roila, M Tonato, F Cognetti, E Cortesi, G Favalli, M Marangolo, ... Journal of Clinical Oncology 9 (4), 675-678, 1991 | 360 | 1991 |
| Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic … M Clavel, JB Vermorken, F Cognetti, P Cappelaere, PHM De Mulder, ... Annals of oncology 5 (6), 521-526, 1994 | 346 | 1994 |
| Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial PA Ascierto, GV Long, C Robert, B Brady, C Dutriaux, AM Di Giacomo, ... JAMA oncology 5 (2), 187-194, 2019 | 344 | 2019 |
| Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double … A Poveda, A Floquet, JA Ledermann, R Asher, RT Penson, AM Oza, ... The Lancet Oncology 22 (5), 620-631, 2021 | 280 | 2021 |
| Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with … H Roché, L Yelle, F Cognetti, L Mauriac, C Bunnell, J Sparano, P Kerbrat, ... Journal of clinical oncology 25 (23), 3415-3420, 2007 | 276 | 2007 |
| Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial A Pace, D Giannarelli, E Galie, A Savarese, S Carpano, M Della Giulia, ... Neurology 74 (9), 762-766, 2010 | 246 | 2010 |
| Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian … F Cognetti, EM Ruggeri, A Felici, M Gallucci, G Muto, CF Pollera, ... Annals of oncology 23 (3), 695-700, 2012 | 245 | 2012 |
